|
The Methodist Neurological Institute
A Randomized, Controlled Clinical Study to Evaluate the Safety and Effectiveness of CortossÆ Synthetic Cortical Bone Void
Filler in Vertebral Augmentation
Investigator: Dr. Hani Haykal
Phone Number: (713) 441-1409
Hydrocoil for Endovascular Aneurysm Occlusion (HEAL) Phase II Patient Registry Protocol Rev. H Jan. 27, 2005
Investigator: Dr. Richard Klucznik
Phone Number: (713) 441-1409
A Phase II, double-blind, randomized, placebo-controlled trial of Atorvastatin (Lipitor) in Amyotrophic Lateral Sclerosis
Investigator: Ericka Simpson, M.D.
Phone Number: (713) 441-5191
Prevalence of Fatigue in Amyotrophic Lateral Sclerosis
Investigator: Ericka Simpson, M.D.
Phone Number: (713) 441-5191
Collection of data and biomaterial for repository banking to facilitate research into the etiology of ALS and related motor
neuron diseases
Investigator: Ericka Simpson, M.D.
Phone Number: (713) 441-5191
Clinical trial of Ceftriaxone in subjects with Amyotrophic Lateral Sclerosis
Investigator: Ericka Simpson, M.D.
Phone Number: (713) 441-5191
Quantification of frontal lobe dysfunction in ALS by Magnetic Resonance (MR) Diffusion Tensor Imaging (DTI)
Investigator: Ericka Simpson, M.D.
Phone Number: (713) 441-5191
Trial of Insulin-like Growth Factor-1 (IGF-1) in Patients with Amyotrophic Lateral Sclerosis (ALS)
Investigator: Stanley Appel, M.D.
Phone Number: (713) 441-5191
A Multi-center, phase III, randomized, double-blind, placebo-controlled, clinical trials of minocycline in 40 subjects with
ALS
Investigator: Stanley Appel, M.D.
Phone Number: (713) 441-5191
An open-label multi-center study to assess the safety of AVP-923 (Dextromethorpahn/Quinidine) in the treatment of patients
with pseudobulbar affect
Investigator: Stanley Appel, M.D.
Phone Number: (713) 441-5191
Resequencing the Human Genome in Sporadic ALS: A Necessary Preclude to Diagnostic and Drug Development
Investigator: Stanley Appel, M.D.
Phone Number: (713) 441-5191
|
